Medical Oncologist
CION Cancer Clinics
A residual mass after chemotherapy: surgery or surveillance? | CION Cancer Clinics
Whether a mass left after chemotherapy is removed or watched depends mainly on the type of testicular cancer. In non-seminoma, a clearly visible mass is usually removed, even with normal blood markers, because it may hold teratoma that scans cannot rule out. In seminoma, most leftover masses are watched, with PET-CT helping to find the few that need more. This page explains what your team weighs. CION Cancer Clinics’ surgical oncologists in Hyderabad can talk this through with you.
MM
Medically reviewed by Dr. Muralidhar MuddusettyConsultant Surgical Oncologist · MBBS (AIIMS), MS (Surgery, AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh) · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Should a mass left after chemotherapy be removed or watched?
- What can be inside the mass?
- How do the decisions differ for non-seminoma and seminoma?
- How does your team reach the decision?
- What does watching actually involve?
- What do families get wrong about a leftover mass?
- Which words will you see on your reports?
- Common questions about a residual mass after chemotherapy
The short answer
Should a mass left after chemotherapy be removed or watched?
It depends mainly on the type of testicular cancer. For non-seminoma, a mass still clearly visible after chemotherapy is usually removed, even when blood markers are normal, because it can hold teratoma or live cancer that scans cannot rule out. For seminoma, most leftover masses are watched, and a PET-CT helps decide the few that need more treatment.
What a residual mass is
Before chemotherapy, the scan showed enlarged lymph nodes at the back of the abdomen. Chemotherapy shrinks them. A residual mass is whatever is still there on the scan afterwards. Its size alone does not tell anyone what is inside it.
Why the type of cancer changes everything
Non-seminoma can leave behind teratoma, a kind of tumour tissue that chemotherapy does not kill and that can grow slowly for years. Seminoma does not leave teratoma, and its leftover masses are usually scar tissue that shrinks further with time. That single difference is why the two paths look so different.
Your treating team, often after a tumour board discussion, makes this decision. This page explains what they weigh.Three possibilities
What can be inside the mass?
Only the laboratory can say for sure, once the tissue is removed and examined. These are the three things it usually finds.
Dead tissue and scar
The cancer was killed by chemotherapy and only scar remains. The report may call it necrosis or fibrosis. This is the most common finding, and no further treatment is needed for it.
Teratoma
Tissue that chemotherapy cannot kill. It may look harmless under the microscope, but it can grow, press on organs, or rarely turn into a different cancer. Removing it is the only treatment.
Live cancer
Cancer cells that survived chemotherapy. This is the least common finding when markers are normal. If found, your team will discuss whether more chemotherapy is needed after surgery.
Not sure whether this applies to you?
Ask an oncologistSide by side
How do the decisions differ for non-seminoma and seminoma?
Non-seminoma
Seminoma
A clearly visible mass is usually removed by RPLND
Most masses are watched with scans and markers
PET-CT is not used to decide, because teratoma does not show up on it
PET-CT, done some weeks after chemotherapy, helps pick out masses that need more
Very small leftover nodes may be watched in some centres
Surgery is harder, because seminoma scar sticks tightly to vessels
Main worry: teratoma left behind
Main worry: live seminoma left behind
The pathway
How does your team reach the decision?
-
Blood markers after chemotherapy
AFP, beta-hCG and LDH are checked. If they have returned to normal, surgery or watching is discussed. If they are still raised or rising, more treatment is usually considered first.
-
A CT scan to measure what is left
The scan is compared with the one taken before chemotherapy. The size, shape and position of the mass all matter, including whether it touches the major blood vessels.
-
PET-CT, for seminoma
Timed after the body has settled from chemotherapy, because an early scan can light up from healing tissue alone.
-
Tumour board review
Medical oncologists, surgeons and radiologists look at the scans together, alongside the original testicle report.
-
The plan is explained
Either an operation, with the template and risks, or a surveillance plan with dates for scans and blood tests. Bring a family member.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
The other path
What does watching actually involve?
Watching, or surveillance, is an active plan, not waiting and hoping. You have regular scans and blood marker tests on a schedule your team sets. If the mass grows or markers rise, the plan changes.
Who surveillance suits
Most men with seminoma and a leftover mass that does not light up on PET-CT. Some men with non-seminoma whose leftover nodes are very small, at centres that follow this approach. It suits men who can keep every appointment, sometimes for years.
Who it does not suit
It does not suit men with non-seminoma whose mass is clearly measurable, men whose original testicle showed teratoma, or anyone who cannot reliably return for follow-up. Missing scans in a surveillance plan removes the safety it depends on.
A mass that grows while markers stay normal
In non-seminoma, this usually means teratoma is growing. It is sometimes called growing teratoma syndrome. It is not a failure of chemotherapy in the usual sense, and it is treated by removing the mass, not by more chemotherapy.
Commonly believed
What do families get wrong about a leftover mass?
"The markers are normal, so the mass must be harmless."
Teratoma does not raise blood markers. A normal result rules out a lot, but not teratoma. That is why a visible mass in non-seminoma is often removed despite normal blood tests.
"Chemotherapy did not work, since something is still there."
Most leftover masses are scar tissue, dead tissue or teratoma. Chemotherapy often did exactly what it could. The mass is simply what it could not dissolve.
"A clear PET-CT means we can skip surgery."
For seminoma, a clear PET-CT is reassuring. For non-seminoma, it is not enough, because teratoma often does not light up. Ask which type you have before reading a PET-CT result as good news.
"Let us finish chemotherapy and rest a year before deciding."
Timing is set by your team. A long unplanned gap lets teratoma grow and stick to vessels, making surgery harder. Ask for the decision date and keep it.
On your report
Which words will you see on your reports?
- Seminoma / non-seminoma
- The two main types of testicular germ cell cancer. Your original testicle report says which you have.
- Residual mass
- Tissue still visible on the scan after chemotherapy has finished.
- Tumour markers
- Blood tests, AFP, beta-hCG and LDH, that can rise when some testicular cancers are active.
- Teratoma
- Tumour tissue that chemotherapy does not kill and that does not raise markers.
- Necrosis / fibrosis
- Dead tissue and scar, meaning the cancer in that area has been killed.
- PC-RPLND
- Post-chemotherapy RPLND, the operation that removes the leftover mass and nearby nodes.
Questions we are asked
Common questions about a residual mass after chemotherapy
Does a residual mass mean the cancer is still there?
Not necessarily. Most leftover masses turn out to be dead tissue or scar. Some hold teratoma, and fewer hold live cancer. Scans cannot reliably tell these apart, which is why your team either removes the mass for testing or watches it closely, depending on the type of cancer.
Why is surgery advised if my markers are normal?
In non-seminoma, teratoma does not raise blood markers and does not respond to chemotherapy. A normal blood test cannot rule it out. Removing the mass is the only way to know what is inside and to deal with teratoma if it is there. Ask your team how your scans shaped this advice.
Can a PET-CT decide for me instead of surgery?
For seminoma, PET-CT is helpful and often used to decide between watching and more treatment. For non-seminoma it is not reliable, because teratoma usually does not light up. Your team will tell you whether a PET-CT adds anything in your case.
How soon after chemotherapy is the operation done?
Usually once you have recovered from chemotherapy, your blood counts have settled and the scans and markers have been reviewed. The exact timing is set by your team. Ask for a date, because a long unplanned delay can make the operation harder if teratoma is present.
Is surgery after chemotherapy riskier than a first RPLND?
Generally yes. Scar tissue from chemotherapy can stick the mass to large blood vessels and nearby organs, and the operation is often longer. Ejaculation nerves are harder to spare. This is why post-chemotherapy RPLND is best done by a team with regular experience of it.
What happens if the mass grows during surveillance?
Your team will repeat markers and scans and meet again to review. If markers are normal and the mass is growing, surgery is often advised, because teratoma is the usual cause. If markers are rising, more treatment may be discussed first.
Will I need more chemotherapy after the operation?
Only if the laboratory finds live cancer, and even then not always. If the mass is dead tissue or teratoma that was fully removed, no further chemotherapy is usually needed. Your follow-up plan will depend on the final report.
Can we get a second opinion on operate or watch?
Yes, and it is common for this decision. Take the scans from before and after chemotherapy on disc, all marker results, and the original testicle report. A reviewing team needs to compare the two scans directly, not only read the written reports.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Testicular Cancer Treatment (PDQ) - Health Professional Version
- National Cancer Institute — Testicular Cancer Treatment (PDQ) - Patient Version
- American Cancer Society — Surgery for Testicular Cancer
- Cancer Research UK — Testicular cancer: treatment
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Primary vs post-chemotherapy RPLNDHow the operation differs once chemotherapy has been givenWhat the RPLND specimen showsReading the report on the tissue that was removedTemplates: full bilateral vs modifiedHow much is cleared after chemotherapyPET-CT scan guideWhat a PET-CT can and cannot showDeciding on cancer surgeryWeighing an operation against watching
Talk to us
Have a scan showing a leftover mass?
Send us the scans from before and after chemotherapy, or call the helpline. A surgical oncologist will go through them with you and help you prepare questions for your team. One helpline serves every CION centre.